Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Growth in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 1,180.7% from the January 15th total of 211,600 shares. Based on an average daily volume of 17,180,000 shares, the short-interest ratio is presently 0.2 days. Approximately 25.5% of the company’s shares are sold short.

Institutional Investors Weigh In On Hepion Pharmaceuticals

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Anson Funds Management LP bought a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals at the end of the most recent quarter. 17.24% of the stock is currently owned by institutional investors.

Hepion Pharmaceuticals Stock Down 0.5 %

Shares of Hepion Pharmaceuticals stock traded down $0.00 during trading on Wednesday, reaching $0.20. 19,712,740 shares of the company were exchanged, compared to its average volume of 40,912,324. Hepion Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.49. The business has a 50-day moving average price of $0.42 and a 200-day moving average price of $0.59. The firm has a market capitalization of $1.38 million, a price-to-earnings ratio of -0.05 and a beta of 1.65.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.